®, the first FDA-approved digital medicine.
Bill currently serves as Chairman of the Board of Directors of OPDC and is also the Chairman of the Board of the Sozosei Foundation, a newly established Otsuka charitable organization focused on decriminalization of mental illness. He serves on the boards of Excision BioTherapeutics, Saama and Annexon Biosciences and is Trustee of the non-profit Internet2. He is Board Chair Emeritus of the Sphinx Organization, which advocates for parity and inclusion in the arts.
“Bill is an eminent figure in the biopharmaceutical community with a proven track record of advancing therapies through clinical development, regulatory approval and commercialization. His appointment demonstrates our ambition to establish Decibel at the forefront of innovation in treatments to restore and improve hearing and balance,” said Laurence Reid, Ph.D., Chief Executive Officer. “Bill is passionate about delivering life-changing therapies in areas of unmet medical
binx health Raises $104 Million in Series E Financing
- Financing led by OrbiMed, and includes Arrowmark Partners, Hildred Capital Management, Alta Life Sciences and Parian Global -
- Proceeds to support expansion of manufacturing for first-of-kind, FDA-cleared, CLIA-waived binx io rapid molecular diagnostic test, menu expansion, and the company s data and software architecture for its at-home and in-clinic businesses -
News provided by
Share this article
Share this article
BOSTON, May 27, 2021 /PRNewswire/ binx health, a healthcare technology and diagnostics company that makes routine testing convenient by enabling access to care where people live, work, study and shop, today announced the closing of a Series E financing of $104 million. The financing was led by OrbiMed, and included other new investors Arrowmark Partners, Hildred Capital Management, Alta Life Sciences and Parian Global, along with existing investors LSP and Johnson and Johnson Development Corporation, am
4D pharma plc: 4D pharma Presents Additional Positive Results of Phase II Study of Blautix for the Treatment of Irritable Bowel Syndrome finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
European Commission decision anticipated in JulyBOSTON, May 21, 2021 (GLOBE NEWSWIRE) Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming
G2 Bio Companies Launch with US$200 Million to Develop Transformative Genetic-Based Therapies streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.